The retina is constantly exposed to light that increases reactive oxygen species in retina. Oxidative stress, inflammation and neurodegeneration are the major contributors in the most common retinal diseases, such as agerelated macular degeneration (AMD), glaucoma and diabetic retinopathy (DR). Emerging developments and research for novel therapy targets and drug delivery to the posterior segment offer a promising future for the treatment of retinal diseases including rare hereditary diseases. In this review we discuss about promising mechanistical retinal drug targets. Vascular endothelial growth factor (VEGF) signaling and anti-VEGF treatments are excluded.
Introduction
The mature retina is organized into three nuclear layers; ganglion cell layer (GCL), inner nuclear layer (INL) and outer nuclear layer (ONL) that are interconnected by synapses [ Fig. 1 ]. Retinal ganglion cells (RGCs) form the most inner layer of retinal cells. Their axons form the optic nerve and transmit visual information into the visual cortex. RGCs undergo apoptotic cell death in glaucoma and other optic neuropathies [1] . The mechanisms of RGC death are still a matter of intense investigation, and several factors including growth factor deprivation and oxidative stress have been proposed to participate in RGC degeneration in glaucoma. Rod and cone photoreceptors of the ONL are the light sensing cells of the eye that are responsible for black/white and colour vision respectively. The photoreceptors initiate the phototransduction, which leads to the action potential in retinal ganglion cells. The retinal pigment epithelial (RPE) cells are situated between the photoreceptor cells and the choroid [ Fig. 1 ]. The RPE cells are vitally important for vision by maintaining the viability of photoreceptor cells [2] [3] [4] . Daily phagocytosis of photoreceptor outer segments (POS) and their degradation in RPE cell lysosomes (heterophagy) are critical for visual cycle and maintaining vision [4] [5] [6] . RPE cells are phagocytically the most active cells in the whole body, uptaking and degrading up to 10% of the POS daily. Apical microvilli of the RPE extend around the POS and ingest shed rod and cone outer segment discs into the RPE as membranebound phagosomes [2] . These phagosomes fuse with lysosomes to form phagolysosomes. Lysosomal acid hydrolases degrade the outer segment material that is re-used in photoreceptors. The degradation process is critically controlled by acidification of lysosomes with vacuolar-type H + -ATPases (V-ATPase) [7] . Decreased lysosomal enzyme activity evokes an accumulation of lipofuscin, increases oxidative stress and protein aggregation and enhances RPE degeneration. We discuss about promising drug targets that coincide with normal cellular homeostasis in retina.
Targeting phagocytosis
Phagocytosis processes comprise recognition and binding, internalization, and finally digestion of POS discs in lysosomes [8; Fig. 2 ]. [9, 10] . Initially, the integrin ITGAV-ITGB5 (αVβ5) regulates the binding process [11, 12] . Subsequently, MERTK (c-mer proto-oncogene tyrosine kinase) enhances the POS ingestion [13, 14] . MERTK phosphorylates protein tyrosine kinase 2 during the binding process and links the signaling between integrin ITGAV-ITGB5 and MERTK [15, 16] . Efficiency of phagocytosis varies according to circadian rhythm which is controlled by MFGE8 (milk fat globule-EGF factor 8 protein [17] ). It is widely accepted that defects in phagocytosis are detrimental to photoreceptors and RPE [13, 14, 18] . It has been documented that decrease of integrin ITGAV-ITGB5 associates with the accumulation of lipofuscin in RPE cell lysosomes. Lipofuscin is a heterogenous protein-lipidcarbohydrate aggregate which includes toxic fluorophores such as, Nretinylidene-N-retinylethanolamine (A2E) compound. Lipofuscin toxic compounds disturb lysosomal membrane stability, inhibits mitochondrial respiration and accelerate RPE degeneration [18] . Thus, regulatory proteins of POS phagocytosis are critical pharmaceutical targets to maintain retinal homeostasis. In addition, for improving the POS clearance, many modulators of visual cycle have been developed in order to treat various retinal diseases [ Fig. 2 ]. These agents were designed to inhibit retinoid isomerase [retinal pigment epithelium-specific 65 kDa protein (RPE65)], the rate-limiting enzyme of the visual cycle, based on the idea that an attenuation of visual pigment regeneration could reduce the formation of toxic retinal conjugates [19, 20] .
Targeting autophagy
In addition to POS phagocytosis, lysosomal degradation of cytosolic material in a process called autophagy is a key therapy target in agerelated retinal diseases [ Fig. 2 ]. Disturbed lysosomal clearance leads to RPE degeneration, which can clinically be observed by pigment mottling, increased autofluorescence and accumulation of extracellular drusen deposits. All those are hallmarks of increased cellular stress and RPE degeneration process that one day may lead to cell death [21] .
Constant oxidative stress induces protein misfolding and aggregation if heat shock proteins (Hsps, molecular chaperones), proteasomes, or the protective capacity of autophagy have been exceeded [22] . Hsps working with the ubiquitin proteasome system and autophagy, are responsible for cellular quality control. Essential tasks of Hsps include assistance in the refolding of damaged proteins, facilitation their translocation to correct intracellular localizations, and mitigation of the harmful effects of protein misfolding and aggregation [23] . Hsprelated chaperone therapy has been discussed to be potentially preventive in the progression of retinal neurodegenerative diseases. Soluble damaged proteins are targeted to proteasomes for degradation, while larger proteins complexes undergo the autophagy clearance. Dysfunctional autophagy has been associated with several neuropathological conditions and a considerable number of studies have proved autophagy as a potential target for pharmacological modulation to achieve cellular protection in ganglion cells, photoreceptors, and in RPE cells [25] [26] [27] [28] [29] [30] .
Yoshinori Ohsumi was awarded with the Nobel Prize 2016 in Physiology or Medicine for his efforts on autophagy research [31] . Autophagy is an intracellular degradation process that removes long-lived or aggregated proteins, lipid droplets, and organelles from the cytoplasm in all eukaryotic cells [32] . Autophagy is host defence response to many environmental stresses observed in retinal diseases such as, nutrient deprivation, hypoxia, or oxidative stress. In autophagy cellular energy is reused by recycling free fatty acids, amino acids and nucleotides after their degradation process [22, 33] . The autophagy process undergoes the enlarging of autophagosome membrane from omegasome origin to the mature double-membrane autophagosome. The autophagosome itself is not active in degradation process. Once the autophagosome fuse with lysosomes, lysosomal enzymes are released into autophagosome cavity and start degrade its contents. There is strong evidence that pharmacological induction of autophagy improves cellular survival [25, 34, 35] . Adenosinemonophosphateactivated protein kinase (AMPK) is a key energy and stress sensor that regulates the cellular metabolism. AMPK stimulates autophagy by inhibiting mTOR complex 1 (mTORC1), a major negative regulator of autophagy [36] . mTOR belongs to the PI3K-related kinase family. It consists of the central regulatory catalytic core of two functionally distinct multiprotein complexes, mTORC1 and mTORC2. Rheb, Raptor, PRAS40-P, mLST8 and Deptor are regulatory units for mTORC1, while Sin1, Rictor, mLST8 and Protor are the corresponding units for mTORC2 [ Fig. 2 ]. mTORC1 regulates autophagy rather than mTORC2 which is involved in the control of cytoskeleton organization and cell survival. The modulation of mTORC1 function is a potential target for the development of therapeutics for neurodegenerative diseases including retinal diseases. Rapamycin, sirolimus, temsirolimus (CCI-779), everolimus (RAD-001), deferolimus (AP-23573) are examples of mTORC1 inhibitors. Metformin, resveratrol and adenosine analogue 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) activate AMPK and inhibit mTOR [24, 33, 34; Fig. 2] . Autophagy is also required to support daily phagocytosis within RPE cells and keep retinoid levels for vision [4, Fig. 1 ]. Decline in retinal clearance system may lead to increased oxidative and endoplasmic reticulum stress, mitohondrial damage, and inflammation [37] [38] [39] .
Targeting the endoplasmic reticulum and mitochondria
Oxidative stress refers to the progressive cellular damage caused by reactive oxygen species, contributing to protein misfolding, and evoking functional abnormalities during the cellular senescence of the RPE cells [40] . Free radicals also damage the lysosomes of RPE cells, which lose their capacity to degrade photoreceptor outer segment material, resulting in the accumulation of lipofuscin-a recognized hallmark of ageing [41, 42] . Lipofuscin contains vitamin A-derived fluorophores that has been shown to inhibit mitochondrial respiration and increase endoplasmic reticulum stress (ER) [40-42; Fig. 1 ]. To maintain proteostasis and cell function, the ER activates an adaptive quality control measure known as the unfolded protein response (UPR). The UPR is initiated by three independent transmembrane stress transducers; 1) inositol-requiring kinase-1 (IRE1), 2) double-stranded RNAactivated protein kinase-like ER kinase (PERK), and 3) activating transcription factor-6 (ATF6) [43] [44] [45] [46] . There is evidence of autophagy-ERmitochondrial crosstalk in RPE cells and the AMD development [22, 47] . ER-mitochondria contact sites are involved in the autophagosome formation, and many proteins in the mitochondriaassociated ER membrane (MAM) compartments are necessary for the autophagic vesicle formation [45; Fig. 2 ]. Humanin (HN) is a prominent member of a newly discovered family of mitochondrial-derived peptides (MDPs) expressed from an open reading frame of mitochondrial 16S rRNA [47] . The more potent variant humanin G (HNG) protects the RPE mitochondria and ER, and reduces apoptosis at both gene and protein levels [46,47; Fig. 2 ]. The therapeutic use of HN could potentially prove to be a valuable approach for the treatment of AMD.
Inflammatory pathways as therapeutic targets

Retinal defence system
Inflammation is known to be involved in various retinal degenerative diseases, and properly controlled inflammation would be a novel approach for therapy [48] [49] [50] . Retina is an immune privileged tissue due to (1) the blood retinal barriers (BRBs) that prevent the free migration of circulating immune cells and molecules into the retinal parenchyma, and (2) the immunosuppressive microenvironment of the retina. The "privilege" ensures that the retina is not affected by systemic immune system under normal physiological conditions. During systemic infection, a small number of circulating immune cells may infiltrate the retina [51] , but they only induce inflammation when encounter specific antigens. When the retina suffers from exogenous or endogenous insults, the first line of defence is the retinal innate immune system rather than circulating immune cells. This may be a strategy to minimise retinal immune response, therefore protecting the neuroretina from inflammation-mediated damage.
As an immune privileged tissue, the retina has its own defence system, including resident immune cells and the complement system, although under normal physiological conditions their activity is suppressed by the microenvironment. Microglia are the main resident immune cells of the retina. Microglia are distributed in three layers of the neuronal retina, the ganglion cell layer (GCL), the inner plexiform layer (IPL), and the outer plexiform layer (OPL) [52] . They can quickly respond to exogenous pathogens and endogenous danger molecules, and become activated. Active microglia phagocytise invading pathogens, dead cells, or damaged molecules and play an important role in retinal homeostasis [53, 54] . Microglial activation is tightly regulated by various membrane or soluble molecules released by surrounding neurons. Examples of the inhibitory pathways include the CX3CL1/ CX3CR1, CD200/CD200R, SIRP/CD47, and the endocannabinoids/cannabinoids receptors (CB1, C2) pathway [52] . Active microglia are highly phagocytic and play an important role in the clearance of retinal dead cells and debris [53] . However, uncontrolled microglial activation is known to contribute to many retinal pathologies, such as photoreceptor degeneration, and retinal angiogenesis [53, 54] . How this protective response becomes detrimental in retinal degenerative diseases remains poorly defined. Active microglia may release inflammatory molecules such as TNF-α, IL-1β, and CCL2 that may directly kill retinal neurons or may escalate inflammation by recruiting circulating immune cells.
When retinal diseases progress towards the advanced stages (e.g., neovascular AMD or proliferative diabetic retinopathy), retinal immune privilege may be compromised due to breakdown of the BRB. Circulating immune components including leukocytes and complement proteins may infiltrate the retina and participate in retinal immune response. Extending treatment strategies to systemic immune regulation might be necessary.
Targeting microglial activation
When targeting microglial activation for therapy, it is important to ensure that the beneficial role of microglia is preserved when eliminating the detrimental roles (Fig. 1) . Microglia is activated upon engaging exogenous or endogenous pathogens/danger molecules using cell surface or cytosolic pathogen recognition receptors (PRRs) [55] , including Toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs). After engaging with relevant ligands, the PRR-associated kinases, such as the interleukine-1 receptor-associated kinase (IRAKs) and the receptor-interacting protein (RIP), are activated (phosphorylated), leading to a cascade of intracellular signal transduction and inflammatory gene and protein expression. Corticosteroids are widely used to control retinal inflammation and they can certainly suppress microglial activation. However, their application is limited, particularly in chronic retinal degenerative conditions, due to the well-known adverse effects (e.g., induce cataract and increase intraocular pressure). Target-specific and safe antiinflammatory therapies are needed. C5a specific mAb CCX168 C5aR inhibitor Fig. 3 . Key steps of the complement activation cascades and available compounds targeting the complement system. Initiation: The complement system can be activated by at least three pathways, which all lead to the formation of C3 convertase. Amplification: when C3 is cleaved into C3a and C3b, C3b can form C3 convertase with the fragment of factor B (Bb) amplifying the complement activation cascade. C3b is essential for the formation of C5 convertase with C4b or Bb. The effectors of the complement system include C3a, C5a and C5b-9. Complement activation can be effectively controlled at each step.
It would be a risk to block PRRs to control microglial activation as it would jeopardise the protective response of host defence. However, targeting relevant kinase of the PRRs could be a novel approach for the management of uncontrolled microglial activation. IMO-8400 (Iderapharma), a selective antagonist of TLR7, 8, and 9 inhibiting the MyD88 signaling pathway, has been tested in conditions whereby lesions are related to the over-activation of TLRs [56] , such as psoriasis, Waldenstrom's macroglobulinemia (NCT02092909), and dermatomyositis (NCT02612857). Their applications in uncontrolled microglial activation remains to be determined.
Microglia can be activated towards the pro-inflammatory phenotype (classical activated M1 phenotype) or anti-inflammatory/woundhealing phenotype (alternatively activated M2 phenotype) [57] . The former is related to the production of inflammatory cytokines such as TNFα, IL-1β, and nitric oxide, whereas the latter is related to the release of anti-inflammatory, tissue-repair and angiogenic growth factors, including IL-10, TGFβ, CCL22, and VEGF. Modulating microglial activation towards M2 phenotype is believed to be an effective approach to limit inflammatory damage in neuroinflammatory and neurodegenerative conditions. Despite intensive research in this area, clinical translation has not been materialized.
The toxic effect of active microglia is mediated through the release of inflammatory cytokines and chemokines such as TNFα and IL-1β. Therefore, targeting these cytotoxic mediators are also effective approaches of immune therapy. In fact, an anti-TNFα monoclonal antibody has been shown to be effective in the treatment of retinal and CNS autoimmune diseases [58] . It must be noted that inflammatory cytokines can be released by multiple cell types, particularly when the BRB is broken down during retinal inflammation. Apart from active microglia, tissue cells and infiltrating immune cells can all produce inflammatory cytokines. Strictly speaking, anti-TNFα is not a microglia-targeted therapy.
Targeting the complement system
The complement system is an important part of the innate immunity. The majority of complement proteins are produced in the liver and released as a latent form to circulation for systemic distribution. The complement system can be activated by at least three pathways, the classic pathway (CP), the alternative pathway (AP) and the mannose-binding pathway (MBP) [59] . The complement system may participate in immune response at multiple levels. Firstly, complement fragments such as C3a and C5a are anaphylatoxins and may induce vasodilation and smooth muscle contraction. They can also induce immune cell migration and activation through relevant receptor (C3aR, C5aR and C5L2). Secondly, C3b can opsonize pathogens or apoptotic bodies and enhance their clearance by phagocytes. Finally, the end product of complement activation is the formation of C5b-9 (membrane attack complex, MAC), which can lyse target cells, although sublytic levels of MAC may participate in immune modulation [60, 61] .
The complement activation pathway can be targeted at the initiation, amplification, and effector stages (Fig. 3) . Indeed, various compounds have been developed to specifically target different steps of complement activation cascade. Fig. 3 illustrates the key steps of complement activation and the compounds that are currently on trials or approved for treating inflammatory conditions.
As the retina is separated from blood circulation by the BRB, circulating complement proteins cannot reach the retina under normal physiological conditions. We and others have shown that retinal cells, particularly RPE and microglia express various complement proteins [62, 63] . Interestingly, the expression levels of complement regulators (CFH, CD46, CD59, C1INH) are generally higher than those of complement activators (e.g., C3, C5, C6, C7, C8, C9) [63] . We believe that the retina has a complement regulatory system [64] that protects the retina from uncontrolled complement activation under pathophysiological conditions. Under ageing and oxidative conditions, the regulatory system may become dysfunctional leading to uncontrolled complement activation and retinal pathology. For example, CFH, the key regulator of the AP, is highly expressed by RPE cells under physiological conditions [65] . The expression of CFH is down-regulated by inflammatory cytokines and under oxidative stress conditions. On the other hand, the expression of CFB, a key protein required for the AP activation, is increased during ageing [66] . When targeting the complement system for the management of retinal diseases, whether the drug should be administered systemically or locally is an important consideration. Due to the existence of the local complement regulatory system, we think that intraocular administration would be more appropriate even when the BRB is compromised.
Uncontrolled complement activation is known to be involved in a number of inflammatory and degeneration retinal diseases, including uveoretinits, AMD, and diabetic retinopathy. Targeting the complement system for the management of retinal inflammatory and degenerative diseases has been a hot area of research in recent years [64] . When targeting the complement system for therapy, it is important to understand the beneficial and detrimental elements of complement activation in retinal pathology under specific disease conditions. Although inappropriate levels of MAC and C3a/C5a may cause tissue damage, C3b can promote phagocytosis of dead cells and debris and is beneficial for resolution of inflammation and tissue remodelling. Ideally, the therapy should be sufficient to remove unwanted complement activation without shutting down necessary biology response pertinent to tissue repair and homeostasis. The chosen therapies should also consider the mechanism of complement activation, i.e., what triggers complement activation, which complement pathways are involved and at which stages of the disease. In autoimmune uveoretinitis, autoantibody-mediated immune complex may induce the CP complement activation, however the cascade is ultimately amplified by the AP pathway [67] . Therefore, inhibition of the AP can effectively control complement activation in uveoretinitis. If retinal pathology is caused by excessive amount of MAC, targeting the terminal pathway i.e., preventing the assembling of MAC using anti-C5, anti-C6 or over-expression of CD59 would be an ideal approach for therapy. If C3a-or C5a-mediated immune activation underlies retinal pathology, targeting the C3a/C3aR or C5a/C5aR pathway should be considered. Due to lack of mechanistic insights on how the complement system contributes to retinal pathology in aforementioned diseases, current approaches are restricted to the inhibition of complement activation (e.g., C3 or C5 inhibitors or CFD inhibitor, for more details please see details in our recent review article [64] ).
Targeting the inflammasome
Apart from microglia and the complement system, inflammation may also occur in retinal cells, i.e. as a tissue-cell autonomous inflammatory response. Typical example of tissue autonomous inflammation is inflammasome activation in RPE cells [68] . Inflammasomes are multiprotein complex assembled in response to pathogens or danger molecules [65] . The inflammasome complex typically contains a sensor protein, an adaptor protein and a procaspase-1. Inflammasome activation results in the cleavage of inactive procaspase-1 into an active cysteine-protease enzyme, caspase-1, which can activate proinflammatory cytokines IL-1β and IL-18. Inflammasome activation may also lead to pyroptosis, a pyrogenic inflammatory-type of cell death. Inflammasomes can be activated in immune cells (e.g. macrophages) as well as tissue cells that express sensor proteins, such as members of the NLR (NLRP1, NLRP3, and NLRP4) or AIM2-like receptor (ALR) family [69] . Among these, NLRP3-mediated inflammasome activation in RPE cells is the most intensively investigated pathway [70, 71] , and activation of this pathway is known to contribute to the pathogenesis of AMD. NLPR3 can be activated by a wide array of microbe-and hostderived triggers. In the context of retinal inflammatory and degenerative diseases, NLRP3 is likely to be activated by endogenous ligands such as ATP and crystalline substances such as silica and alum [72] . Other events that can induce NLRP3 pathway activation include potassium efflux, the generation of mitochondrial reactive oxygen species (ROS) [73] , cathepsin release from lysosome, and the release of mitochondrial DNA to cytosol [74] . In addition, complement MAC [75] and aluRNA [76] can also activate NLRP3. AluRNA-induced NLRP3 inflammasome activation results in increased IL-18 production, which is known to be involved in the development of geographic atrophy (GA) [76] .
In addition to GA, inflammasome activation is also known to contribute to the pathogenesis of diabetic retinopathy [77] . Targeting the inflammasome pathway may benefit patients with GA and DR. As an innate immune response to endogenous danger stimuli, inflammasome in retinal cells or microglia/macrophages is initially a protective response. Why this protective response becomes detrimental is poorly understood. Although excessive amounts of IL-1β and IL-18 are detrimental, appropriate levels of these cytokines may be required for retinal homeostasis, particularly under chronic stress conditions. RPE cells constantly produce high levels of IL-18 [78] , and NLPR3 inflammasome activation-induced IL-18 has anti-permeability and anti-angiogenic functions and can protect choroidal neovascularization in animal models of AMD [78] . Until we know the exact role of inflammasome activation in retinal homeostasis during ageing and chronic oxidative stress conditions, and how uncontrolled inflammasome activation contributes to retinal pathologies, it will be difficult to safely and effectively target the inflammasome pathways for the management of retinal diseases.
A number of NLPR3-targeted therapies are being developed for the management of cancer and autoimmune diseases [Fig. 4 ]. These are summarised in a recent review by Ozaki et al. [79] Some compounds indirectly target NLRP3 (Glyburide, 16673-34-0), while others target caspase-1 (Pralnacasan -VX-740, VX-765, Parthenolide) and ATP receptor P2X7 (AZD9056; CE-224535; GSK1482169). In addition, antibodies against IL-18 (GSK 1070806) and IL-1β (Canakinumab, Rilonacept) or IL-1 receptor (Anakinra) have also been developed and tested in various conditions related to inflammasome over-activation (e.g. rheumatoid arthritis, B cell non-Hodgkin's lymphoma, inflammatory bowel disease). Once we know precisely the role of inflammasome activation in retinal inflammatory and degenerative conditions, we will be able to apply these compounds to ophthalmic conditions.
Conclusions
Therapeutic strategies for the treatment of AMD coincide with the suppression of oxidative stress and inflammation as well as the maintenance of active clearance mechanisms of the RPE. Pharmacological research should focus on finding new molecular targets in the AMD pathogenetical pathway and on developing longer-lasting agents or new drug delivery systems. Since AMD is complex disease drug development will be challenging especially taking account of personalized medicine. However, possible breakthroughs in AMD treatments may open new therapy options in other retinal diseases.
